For Immediate Release:

UPPI LLC (United Pharmacy Partners) is proud to announce it has received an award from the NNSA Deputy Administrator for Defense Nuclear Nonproliferation Anne Harrington in recognition of its member and affiliate radiopharmacy efforts and initiatives to increase the use of non-HEU-based molybdenum-99 (Mo-99). In a “LEU Walk” campaign, UPPI radiopharmacies encouraged its hospitals and imaging centers to embrace the transition to reliable, low enriched uranium (LEU) based sources of the medical isotopes.

The American Medical Isotope Production Act of 2013 requires the reduction of weapons-grade medical isotope production to non-HEU or LEU sources and supports projects for domestic production. Working in conjunction with Lantheus Medical Inc., UPPI LLC members and affiliates provide LEU Technetium 99m labeled radiopharmaceuticals, the most commonly used imaging radioisotope, needed by the nuclear medicine departments. UPPI LLC clients have shown strong interest by transitioning their facilities to “LEU Walk” products, as a safer source, for their medical imaging requirements.

For more information please contact: Janyce Wender at UPPI, LLC at 770-205-2651.

Please click here for a related Press Release from NNSA:
http://nnsa.energy.gov/mediaroom/pressreleases/mo99partners